Psoriasis is a chronic inflammatory skin disease with a prevalence of about 3%. Patients with moderate to severe psoriasis showing suboptimal response to conventional treatment may be prescribed biologic agents.
This observational study is based on data from the Swedish registry for systemic psoriasis treatment, PsoReg, and analyzes continuously and intermittently treated biologic-naïve patients after switching to a biologic agent.
The results indicate that patients with continuous biologic treatment tend to achieve better outcomes compared to intermittently treated patients, both in terms of Psoriasis Area and Severity Index (PASI) scored and Dermatology Life Quality Index (DLQI) values.
Dermatology, 2015; 230(4): 347-53